Navigation Links
Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
Date:4/21/2009

sion (abstract #3594) during the American Association for Cancer Research's 100th Annual Meeting 2009 at the Colorado Convention Center in Denver.

Phase 1 Study Design and Results

Poniard's randomized, open-label, dose-ranging Phase 1 study was conducted at clinical sites in the United States. The trial compared the bioavailability, pharmacokinetics, pharmacodynamics and safety of picoplatin administered orally with picoplatin administered intravenously to patients with advanced solid tumor malignancies. Bioavailability refers to the fraction of an administered dose of an unchanged drug that reaches systemic circulation. In the first part of this two-part trial, patients with advanced solid tumor malignancies were randomized to a single dose of either intravenous (120 mg/m squared) or oral picoplatin (200 mg, 300 mg or 400 mg). Four weeks later, they received a second single picoplatin dose administered via the other route. In the second part of the trial, patients received only a single oral dose of picoplatin (including doses of 50 mg and 100 mg).

Final results showed that oral picoplatin achieved oral bioavailability of nearly 100 percent at doses of 50 mg and 100 mg. No meaningful differences in pharmacokinetics were observed between the two formulations. All doses of the oral dose were well tolerated. No serious adverse events related to treatment were noted following administration of the oral dose.

About Picoplatin

Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date suggest that it has an improved safety profile relative to existing platinum-based cancer therapies. More than 1,100 patients have received picoplatin. Results obtained to date suggest manageable hematologic adverse events with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other pl
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
3. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
4. Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
5. Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer
6. Poniard Pharmaceuticals Receives Going Concern Qualification
7. Poniard Pharmaceuticals to Present at Needham & Companys Cancer Therapeutics: Today & Tomorrow Conference
8. Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization
9. Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... ... The 2nd annual Ride to Fight On will start and end near ... Ride to Fight On is a cycling fundraiser that benefits the West Cancer Center, ... The University of Tennessee Health Science Center. A health and wellness festival featuring food, ...
(Date:7/31/2015)... ... 31, 2015 , ... There’s no better way to enjoy the summer weather ... cook the next meal, making July the most appropriate to be National Hot Dog ... recipes. , Make the next cookout different than the ones in the past. Celebrate ...
(Date:7/31/2015)... ... 31, 2015 , ... Facebook, Twitter, Linkedin and blogs are ... media profiles to better connect with the public. The agency website at ... insights and opinions. The Rally Insurance Group, Inc.’s pledge to provide effortless ways ...
(Date:7/31/2015)... Fort Washington, PA (PRWEB) , ... July 31, 2015 , ... ... medical specialties, is excited to launch three new Board Exam Courses. , The ... The Smartest Doc Board Exam Prep from MDLinx makes preparing for the exam easy ...
(Date:7/31/2015)... Angeles, CA (PRWEB) , ... July 31, 2015 , ... According to the article ... third floor of the Pasadena courthouse was contained and extinguished by the city’s fire department ... was in the building at the time of the fire, and it was a fire ...
Breaking Medicine News(10 mins):Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3
... 31 On April 1, the federal cigarette tax will ... pack, to fund the expansion of the State Children,s Health ... A new survey shows that the April 1st federal ... concerns for smokers and will change their current smoking habits.(2)The ...
... Health today announced that its Clinical and Medical ... off later this year as CareFusion Corporation, will ... six months and eliminate an additional 500 positions ... addition, Cardinal Health will implement cost control measures ...
... Scientific Company (ESC) is demonstrating a critical technology ... which link healthcare enterprises into the Nationwide Health ... Management Systems Society (HIMSS) conference, April 5-8, 2009. ... problem healthcare enterprises face in providing interoperable, authorized ...
... testimony today before the U.S. Senate Committee on Agriculture, ... revise school food nutrition standards so that more nutritious ... federal nutrition standards for foods sold outside of the ... updated since the late 1970s. , ...
... Infusing cells into damaged area helped restore blood flow, ... Treating a heart attack with the patients, own bone ... and may help reduce long-term complications, a new U.S. ... underwent angioplasty and stent placement after a heart attack. ...
... for dieters who face food challenges in the break room every ... shows that our resistance gets a boost after we,ve just ... a real one for many of us. It is all too ... with their desire to smoke or to drink alcohol or to ...
Cached Medicine News:Health News:Federal Cigarette Tax Increase and Current Economy Will Change Smoker's Habits 2Health News:Federal Cigarette Tax Increase and Current Economy Will Change Smoker's Habits 3Health News:Federal Cigarette Tax Increase and Current Economy Will Change Smoker's Habits 4Health News:Cardinal Health to Reduce Workforce to Respond to Economic Conditions 2Health News:Cardinal Health to Reduce Workforce to Respond to Economic Conditions 3Health News:Edmond Scientific Company Demonstrates RHIO/HIE Data Security and Privacy Solution for the NHIN at Annual HIMSS Conference, Chicago '09 2Health News:Mars Snackfood Urges U.S. Congress to Update National School Nutrition Standards 2Health News:Mars Snackfood Urges U.S. Congress to Update National School Nutrition Standards 3Health News:Patient's Own Stem Cells Might Treat Heart Attack 2Health News:Learning curve: Tricks to resist temptation 2
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 ... Eisai Co., Ltd. (Headquarters: Tokyo , ... Halozyme Therapeutics, Inc. (Headquarters: San Diego, California ... , "NASDAQ: HALO") have signed a clinical collaboration agreement ... , "eribulin") in combination with Halozyme,s investigational drug PEGPH20 ...
(Date:7/31/2015)... July 31, 2015 Magnaquest, ... video, data and cloud computing operators has signed ... pharma giant for Internet of Things (IoT) related ... offered on subscription model.      (Logo: ... is striving for business innovations to make healthcare ...
(Date:7/30/2015)... DIEGO , July 30, 2015 /PRNewswire/ ... it has signed a definitive agreement to ... of non-invasive ventilation and sleep-disordered breathing medical ... clinical, innovation and market reputation in China, combined with ResMed,s global leadership in ... people in China ...
Breaking Medicine Technology:Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... N.J. , May 11 Nearly one-third ... alone, and not in combination with other asthma control ... Drug Administration (FDA) on the risk of worsening asthma ... to a new study from the Medco Research ...
... The DNA Medicine Institute announced today that it has received a ... Gates Foundation.  The grant will support an innovative global health research project ... for Malaria." , , , ... project is one of 78 grants announced by the Gates Foundation in ...
Cached Medicine Technology:Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations 2Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations 3Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations 4Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations 5DNA Medicine Institute Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research 2DNA Medicine Institute Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research 3
... Finntips have been designed to optimize the ... of our tip products is widely recognized ... range has been extended over the years ... standard and special tips including filter tips, ...
This 10 L tip was designed for the Pipetman P-2 and P-10. Its MicroPoint design and 2 L reference mark make it ideal for low volume pipetting....
... Peroxidase stain is the gold standard ... better agreement with your technologists manual ... efficiency. ,True RBC morphology advances cell ... allows for the differentiation of various ...
... Resistant Tips offer a safe alternative to ... designed for applications such as PCR(a), pipetting ... ART Tips are excellent for tissue culture, ... ART Tips prevent aerosol contaminants and liquids ...
Medicine Products: